Print this page
-
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-Stage Triple-Negative Breast Cancer.
Protocol: 042304Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.
Protocol: 042201Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST)
Protocol: 132307Principal Investigator:
- Anita Kinney PhD,RN (Rutgers University)
Applicable Disease Sites: Pancreas
Other Female Genital
Prostate
Colon
Ovary
Breast -
Cancer Analytics and South Asian Health Breast Cancer Survivor Study (CANSAH-BC).
Protocol: 132204Principal Investigator:
- Jaya Satagopan PhD (School of Public Health)
Applicable Disease Sites: Breast -
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Protocol: 042314Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast